Last reviewed · How we verify
early leukostim
Early leukostim stimulates the production of white blood cells.
Early leukostim stimulates the production of white blood cells. Used for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
At a glance
| Generic name | early leukostim |
|---|---|
| Also known as | 2leuko |
| Sponsor | Hyuk moon Kim |
| Drug class | Growth factor |
| Target | G-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Early leukostim works by stimulating the bone marrow to produce more white blood cells, which helps to fight infections and reduce the risk of infection-related complications in patients undergoing chemotherapy.
Approved indications
- Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
Common side effects
- Bone pain
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |